AMPH — Amphastar Pharmaceuticals, Inc.

Summary of Amphastar Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 Revenue: $183.1 million, down 2% from $186.5 million in Q4 2024.
• Full Year Revenue: $719.9 million, a modest decline of 2% year-over-year.
• Net Income: $24.4 million ($0.51 per share), down from $38 million ($0.74 per share) in Q4 2024.
• Adjusted Net Income: $34.2 million ($0.73 per share), compared to $47.2 million ($0.92 per share) in the prior year.
• Operating Cash Flow: $156.1 million for the full year; $32.9 million in Q4.
• Gross Margin: Remained flat at 47% of revenues.

2. Strategic Updates and Business Highlights:

• Product Performance:
  • BAQSIMI sales increased by 12% to $46.7 million, driven by higher U.S. unit volumes.
  • Primatene MIST sales decreased by 3% to $27.9 million.
  • Significant decline in glucagon sales (-45%) and epinephrine sales (-9%) due to increased competition.
• Regulatory Approvals:
  • FDA approvals for iron sucrose, teriparatide, and ipratropium bromide HFA inhalation aerosol (AMP-007), which is expected to launch in Q2 2026.
• Pipeline Expansion: Introduction of three novel peptides in oncology and ophthalmology, and a synthetic corticotropin program in immunology.

3. Forward Guidance and Outlook:

• 2026 Revenue Expectations: Anticipated mid- to high-single-digit growth, driven by BAQSIMI, Primatene MIST, and the launch of ipratropium bromide.
• Gross Margin Outlook: Expected to decline due to pricing pressures on glucagon and epinephrine, along with rising input costs.
• R&D Spending: Increased focus on clinical trials and capital spending for the Rancho Cucamonga facility expansion.
• Cash Position: Over $300 million available, with plans for stock buybacks and potential business development opportunities.

4. Challenges and Points of Concern:

• Legacy Product Pressures: Competitive pressures are impacting sales of glucagon and epinephrine, leading to significant revenue declines in these areas.
• International Sales Decline: Planned discontinuation of unprofitable international markets for BAQSIMI may offset U.S. growth.
• Margin Pressures: Anticipated lower gross margins due to pricing pressures and increased costs from suppliers.

5. Notable Q&A Insights:

• AMP-110 Development: No current discussions with the FDA regarding the development path; internal discussions are ongoing.
• Business Development Focus: Interest in assets related to endocrinology, oncology, ophthalmology, and immunology.
• Primatene MIST Competition: No immediate competition expected post-patent expiration, with ongoing life cycle management efforts in place.
• Market Dynamics: The company believes the market for inhalation products, particularly with AMP-007, is stabilizing despite past declines.

Overall, Amphastar Pharmaceuticals demonstrated resilience in its core products while navigating challenges in legacy segments. The company is positioned for growth through strategic launches and an expanding proprietary pipeline, though it faces headwinds from competitive pressures and margin constraints.